MSI2 and non-small cell lung carcinoma: We are interested in the radioresistance of MSI2, and knocking down the radiosensitizing effect of MSI2 on lung cancer, either by gene therapy or chemical inhibitor development, has practical clinical applications for improving the efficacy of radiotherapy in NSCLC.